发明名称 NATURAL-KILLER/T-CELL LYMPHOMA (NKTCL) SUSCEPTIBILITY PREDICTION, DIAGNOSIS AND THERAPY
摘要 Natural-Killer T-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL.
申请公布号 US2015292022(A1) 申请公布日期 2015.10.15
申请号 US201214360804 申请日期 2012.11.26
申请人 SINGAPORE HEALTH SERVICES PTE LTD 发明人 Teh Bin Tean;Lim Soon Thye
分类号 C12Q1/68;A61K31/519 主分类号 C12Q1/68
代理机构 代理人
主权项 1. A method for predicting Natural Killer T-Cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject, comprising testing for the genotype of said subject for at least one JAK gene or testing for whether said subject expresses a wildtype or mutant JAK protein, wherein the presence of a mutant JAK gene indicates that a subject is at risk of developing and/or has NKTCL.
地址 Singapore SG